TAK-755 not checked

Takeda · Recombinant ADAMTS13 · BAX 930

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
7 in total · 3 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
Main trialPhase 3
“Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause…”In the company’s words, NCT04683003 on ClinicalTrials.gov
Other names
Recombinant ADAMTS13 · BAX 930 · SHP655 · rADAMTS13

Other drugs for Acute Ischemic Stroke

All 45 drugs for Acute Ischemic Stroke

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 16 Mar 2027 A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Phase 2Recruiting 6 Dec 2027 A Study of TAK-755 in Adults With Acute Ischemic Stroke
Phase 3Completed 28 Dec 2023 A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Phase 2Completed 5 Aug 2021 Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Phase 2Completed 16 Apr 2026 A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Phase 1Completed 22 Feb 2016 Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Phase 1Completed 26 Oct 2022 A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TAK-755

Following is part of Solo: you see every change to TAK-755 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in